<DOC>
	<DOCNO>NCT00002765</DOCNO>
	<brief_summary>RATIONALE : Immunotoxins locate cancer cell either kill deliver cancer-killing substance without harm normal cell . PURPOSE : Phase I trial study effectiveness LMB-2 immunotoxin treat patient leukemia lymphoma .</brief_summary>
	<brief_title>Immunotoxin Treating Patients With Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess therapeutic efficacy toxicity recombinant immunotoxin LMB-2 , anti-Tac murine monoclonal antibody fragment conjugate truncated portion Pseudomonas exotoxin , patient Tac-expressing leukemias lymphoma . - Define pharmacokinetics LMB-2 , include terminal elimination serum half-life , area curve , volume distribution . - Evaluate , preliminary manner , immunogenicity LMB-2 patient . - Determine effect LMB-2 various component circulate cellular immune system . OUTLINE : This dose escalation study . Patients receive LMB-2 immunotoxin IV 30 minute day 1 , 3 , 5 . Treatment repeat every 15-21 day 10 course absence disease progression , neutralize antibody , unacceptable toxicity . Cohorts 3-6 patient receive escalate dos LMB-2 immunotoxin maximum tolerate dose ( MTD ) determine . The MTD define dose 1 patient experience dose limit toxicity . PROJECTED ACCRUAL : A maximum 40 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm Hodgkin 's disease , nonHodgkin 's lymphoma , leukemia one follow category : Adult Tcell leukemia lymphoma ( ATL ) No smolder ATL No limitation prior therapy Cutaneous Tcell lymphoma ( CTCL ) Stages IBIII fail least 1 standard therapy Stage IV regardless prior therapy Stages IIV peripheral Tcell lymphoma Relapsed standard chemotherapy Ineligible refuse salvage chemotherapy bone marrow transplantation ( BMT ) Bcell nonHodgkin 's lymphoma ( NHL ) histology Indolent stag IIIV NHL Failed least 1 standard therapy Disease symptomatic require treatment Aggressive NHL Relapsed standard chemotherapy Ineligible refuse salvage chemotherapy BMT Chronic lymphocytic leukemia ( CLL ) Rai stag III IV Binet stage C Failed standard therapy least 1 salvage chemotherapy Primary Bcell prolymphocytic leukemia prolymphocytic transformation CLL Failed standard therapy least 1 salvage chemotherapy Hairy cell leukemia Failed standard salvage chemotherapy Ineligible refuse salvage chemotherapy BMT Acute myelogenous leukemia Failed standard chemotherapy Ineligible refuse salvage chemotherapy BMT Stages IIIV Hodgkin 's disease Failed standard chemotherapy Ineligible curative salvage radiotherapy chemotherapy Ineligible refuse BMT Patients leukemias lymphoma easily classified category fail standard therapy ineligible refuse bone marrow transplant Evidence interleukin2 receptoralpha ( IL2Ra ) expression one following : Greater 10 % malignant cell reactive antiTac immunohistochemistry Greater 10 % malignant cell particular site positive FACS Greater 400 IL2Ra site per malignant cell radiolabeled antiTac binding Soluble IL2Ra level great 1,000 U/mL ( normal geometric mean 235 , 95 % confidence level 112502 U ) Hodgkin 's disease measurable disease amenable biopsy No CNS disease require treatment Malignant cell CSF allow judged represent clinically significant leukemic lymphomatous meningitis ( CSF contamination blood ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Greater 2 month Hematopoietic : Absolute neutrophil count great 1,000/mm3* Platelet count great 50,000/mm3* NOTE : *nonleukemic patient Hepatic : AST ALT less 5 time normal Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 50 mL/min Pulmonary : FEV1 , TLC , DLCO great 50 % predict pulmonary mediastinal involvement tumor great one third total thoracic diameter Other : HIV negative Not pregnant Fertile patient must use effective contraception Serum must neutralize 75 % LMB2 tissue culture PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 3 week since prior interferon Chemotherapy : See Disease Characteristics At least 3 week since prior cytotoxic chemotherapy At least 3 week since prior retinoids No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroids unless begin least 3 week prior entry dose increase 3 week prior entry Radiotherapy : See Disease Characteristics At least 3 week since prior wholebody electron beam radiotherapy Other radiotherapy allow within 3 week entry provide less 10 % marrow irradiate measurable disease exists outside radiation port Surgery : Not specify Other : See Disease Characteristics At least 3 week since prior systemic therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>